NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email Stripping out certain one-time items, adjusted per-share earnings were $1.53, ahead of the $1.32 anticipated by analysts.Read More
